CK Life Science Recevies Boost From COVID-19 Test Kit Distribution Deal

This post was originally published on this site
© Reuters. © Reuters.

By Gina Lee – Hong Kong’s CK Life Sciences International Holdings Inc (HK:) saw its stock jump on the back of Wednesday’s deal to distribute COVID-19 rapid test kits.

The company will distribute the rapid test kits manufactured by Singapore-based medical technology company Biolidics (SI:) in Hong Kong, said a Wednesday press release.

Biolidics received provisional authorization from Singapore’s Health Sciences Authority, and the test kit is already in use in Singapore.

CK Life Sciences’ Hong Kong stocks jumped 12.77% to HK$1.060 by 12:28 AM ET (5:28 AM GMT) on Thursday, whilst Biolidics’ Singapore stocks rose by 3.28%.

Meanwhile, parent company CK Hutchison Holdings (HK:) saw its Hong Kong stocks slide 1.44% to HK$56.28. 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.